Search results
Results from the WOW.Com Content Network
The recalled medicine is Kirkland Signature brand's "Severe Cold and Flu Plus Congestion" medication, sold between Oct. 30 and Nov. 30, 2024. The recalled items have a Lot Code of P140082 on the box.
The recall said the packages bear item number 1729556 and would have been purchased between October 30, 2024 and November 30, 2024. The lot code printed on the back of the affected boxes is P140082 .
Costco shoppers are being urged not to use any remaining product marked with the lot code listed and to return the item to your local Costco for a full refund. You can also reach out to LNK ...
Hydroxycut is a brand of dietary supplements that is marketed as a weight loss aid. Hydroxycut was originally developed and manufactured by MuscleTech Research and Development; MuscleTech was sold to Iovate Health Sciences in 2003–2004 and declared bankruptcy in 2005; Iovate continues to use MuscleTech as a brand to market Hydroxycut.
rhesus rotavirus vaccine-tetravalent (RotaShield) 1999 US Withdrawn due to risk of intussusception. [47] Rimonabant (Acomplia) 2008 Worldwide Risk of severe depression and suicide. [14] Rofecoxib 2004 Worldwide Withdrawn by Merck & Co. Risk of myocardial infarction and stroke. [2] Rosiglitazone (Avandia) 2010 Europe Risk of heart attacks and death.
A high-dose vaccine (Fluzone High-Dose) four times the strength of standard flu vaccine was approved by the FDA in 2009. [22] [23] [24] This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine.
The U.S. Food and Drug Administration (FDA) announced that it plans to ban products containing phenylephrine, an ingredient found in many over-the-counter (OTC) oral cold and flu medications.
According to a 2016 study by faculty at the University of New South Wales, getting a flu shot was as effective or better at preventing a heart attack than even quitting smoking. [105] A 2024 CDC study found that the 2024 flu vaccine reduced the risk of hospitalization from the flu by 35% in the Southern Hemisphere. [106]